Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Growth in Short Interest

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totaling 6,136,786 shares, a growth of 47.4% from the December 15th total of 4,164,492 shares. Currently, 17.2% of the company’s stock are sold short. Based on an average trading volume of 750,490 shares, the short-interest ratio is presently 8.2 days. Based on an average trading volume of 750,490 shares, the short-interest ratio is presently 8.2 days. Currently, 17.2% of the company’s stock are sold short.

Dianthus Therapeutics Trading Up 0.2%

DNTH stock traded up $0.10 during midday trading on Friday, reaching $44.10. 638,611 shares of the company were exchanged, compared to its average volume of 757,049. Dianthus Therapeutics has a one year low of $13.36 and a one year high of $46.59. The business has a 50-day moving average price of $41.43 and a two-hundred day moving average price of $32.70.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Wednesday, November 5th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.11). Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.The company had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.58 million. Equities analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current year.

Insider Buying and Selling

In other news, EVP Simrat Randhawa sold 109,031 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the completion of the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $152,560. This trade represents a 96.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total transaction of $903,600.00. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 216,538 shares of company stock valued at $8,283,175. Insiders own 8.15% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of large investors have recently made changes to their positions in DNTH. Raymond James Financial Inc. bought a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $27,000. Parkside Financial Bank & Trust lifted its stake in Dianthus Therapeutics by 131.7% during the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after purchasing an additional 540 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Dianthus Therapeutics in the third quarter valued at about $64,000. Tower Research Capital LLC TRC grew its position in Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after acquiring an additional 3,317 shares during the last quarter. Finally, AlphaQuest LLC bought a new position in Dianthus Therapeutics in the second quarter valued at about $94,000. Institutional investors own 47.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, October 8th. Wedbush restated an “outperform” rating and issued a $46.00 price target on shares of Dianthus Therapeutics in a research note on Monday, December 22nd. Truist Financial increased their price objective on Dianthus Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Finally, HC Wainwright raised their target price on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $64.43.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.